Legislators
Bills
Statements
Represent

H.RES.161: Expressing the sense of the House of Representatives that the Food and Drug Administration should encourage the use of abuse-deterrent formulations of drugs.

About this Bill

This bill was introduced in the 113th Congress
This bill is primarily about health
You can read the bill
Sponsor Harold Rogers, R-Ky.
Total Cosponsors 7 (4 Democrats, 3 Republicans)
Introduced April 15, 2013
Latest Major Action April 19, 2013
See it on GovTrack
See it on C-SPAN

Bill Progress

  • Bill introduced in the House   
  • Bill passed in the House   
  • Bill passed in the Senate   
  • Bill signed into law

Bill Summary

Expresses the sense of the House of Representatives that the Food and Drug Administration (FDA) should exercise its acknowledged authority to: (1) refuse to approve generic versions of non-abuse-deterrent opioid products that have been replaced in the market with abuse-deterrent formulations, and (2) require generic versions of abuse-deterrent opioid products to be formulated with comparable abuse-deterrent features.

(Source: Congressional Research Service)

Bill Actions

Date Description
April 19, 2013 Referred to the Subcommittee on Health.
April 15, 2013 Referred to the House Committee on Energy and Commerce.